FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313442754> ?p ?o ?g. }

• W4313442754 endingPage "639" @default.
• W4313442754 startingPage "627" @default.
• W4313442754 abstract "Purpose Curative intent treatment of pancreatic adenocarcinoma (PDAC) relies on surgical resection. Modern treatment protocols focus on optimizing neoadjuvant therapy to increase resectability and improve oncologic outcomes. To elucidate differences in outcomes, we investigated the relationship between neoadjuvant chemotherapy (NAC), either with or without stereotactic body radiation therapy (SBRT), and vascular inflammation, surgical outcomes, and the resultant transcriptomic changes. Methods and Materials Clinical data were collected from patients with borderline resectable PDAC (clinical T3-T4N0-1) who underwent NAC or NAC-SBRT followed by curative intent resection between 2014 and 2019. Vascular structures on surgical specimens were histologically evaluated for vasculitis. RNA sequencing was used to evaluate differential gene expression and to generate enrichment maps. Multivariate analysis was used to analyze the relationship between patient characteristics and oncological outcome. Results In total, 46 patients met inclusion criteria (n = 12 NAC, n = 34 NAC-SBRT) with a median follow-up of 20.1 months. All patients underwent curative resection, with 91.3% achieving R0. There was no significant difference in patterns of failure, overall survival, or progression-free survival between NAC and NAC-SBRT groups. Patients with vasculitis had a lower median overall survival compared with those without (14.5 vs 28.3 months; hazard ratio, 12.96; 95% confidence interval, 3.55-47.28; P < .001). There was no significant correlation between inflammation and surgical complications or pathologic response. Neoadjuvant therapy did not have a significant effect on development of vasculitis (odds radio, 1.64 for NAC-SBRT; 95% confidence interval, 0.40-8.43; P = .52). Predictors of poor survival included perineural invasion and high baseline carbohydrate antigen 19-9 (CA19-9) (>191 U/mL). Patients with robust CA19-9 (>20% decrease) responses to neoadjuvant therapy had enrichment in immune response, chemotaxis, and cytotoxic T-cell and natural killer-cell proliferation. Conclusions Vasculitis predicts for poor survival outcomes in patients with PDAC; NAC-SBRT did not increase the rate of vasculitis compared with NAC. Perineural invasion and CA19-9 remain strong prognosticators. Understanding and optimizing immune interactions remain a crucial hurdle in achieving response in pancreatic cancer. Curative intent treatment of pancreatic adenocarcinoma (PDAC) relies on surgical resection. Modern treatment protocols focus on optimizing neoadjuvant therapy to increase resectability and improve oncologic outcomes. To elucidate differences in outcomes, we investigated the relationship between neoadjuvant chemotherapy (NAC), either with or without stereotactic body radiation therapy (SBRT), and vascular inflammation, surgical outcomes, and the resultant transcriptomic changes. Clinical data were collected from patients with borderline resectable PDAC (clinical T3-T4N0-1) who underwent NAC or NAC-SBRT followed by curative intent resection between 2014 and 2019. Vascular structures on surgical specimens were histologically evaluated for vasculitis. RNA sequencing was used to evaluate differential gene expression and to generate enrichment maps. Multivariate analysis was used to analyze the relationship between patient characteristics and oncological outcome. In total, 46 patients met inclusion criteria (n = 12 NAC, n = 34 NAC-SBRT) with a median follow-up of 20.1 months. All patients underwent curative resection, with 91.3% achieving R0. There was no significant difference in patterns of failure, overall survival, or progression-free survival between NAC and NAC-SBRT groups. Patients with vasculitis had a lower median overall survival compared with those without (14.5 vs 28.3 months; hazard ratio, 12.96; 95% confidence interval, 3.55-47.28; P < .001). There was no significant correlation between inflammation and surgical complications or pathologic response. Neoadjuvant therapy did not have a significant effect on development of vasculitis (odds radio, 1.64 for NAC-SBRT; 95% confidence interval, 0.40-8.43; P = .52). Predictors of poor survival included perineural invasion and high baseline carbohydrate antigen 19-9 (CA19-9) (>191 U/mL). Patients with robust CA19-9 (>20% decrease) responses to neoadjuvant therapy had enrichment in immune response, chemotaxis, and cytotoxic T-cell and natural killer-cell proliferation. Vasculitis predicts for poor survival outcomes in patients with PDAC; NAC-SBRT did not increase the rate of vasculitis compared with NAC. Perineural invasion and CA19-9 remain strong prognosticators. Understanding and optimizing immune interactions remain a crucial hurdle in achieving response in pancreatic cancer." @default.
• W4313442754 created "2023-01-06" @default.
• W4313442754 creator A5009011339 @default.
• W4313442754 creator A5017114190 @default.
• W4313442754 creator A5025056006 @default.
• W4313442754 creator A5034675773 @default.
• W4313442754 creator A5049269121 @default.
• W4313442754 creator A5065803127 @default.
• W4313442754 creator A5074475264 @default.
• W4313442754 creator A5076960814 @default.
• W4313442754 creator A5077200492 @default.
• W4313442754 date "2023-07-01" @default.
• W4313442754 modified "2023-10-16" @default.
• W4313442754 title "Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma" @default.
• W4313442754 cites W1532654778 @default.
• W4313442754 cites W1563283949 @default.
• W4313442754 cites W1592992548 @default.
• W4313442754 cites W1969942127 @default.
• W4313442754 cites W1987329654 @default.
• W4313442754 cites W1994177577 @default.
• W4313442754 cites W1997122877 @default.
• W4313442754 cites W2007188602 @default.
• W4313442754 cites W2012555609 @default.
• W4313442754 cites W2031584923 @default.
• W4313442754 cites W2032938778 @default.
• W4313442754 cites W2034983280 @default.
• W4313442754 cites W2043209741 @default.
• W4313442754 cites W2044939971 @default.
• W4313442754 cites W2047318784 @default.
• W4313442754 cites W2060411619 @default.
• W4313442754 cites W2061137918 @default.
• W4313442754 cites W2061995271 @default.
• W4313442754 cites W2095597468 @default.
• W4313442754 cites W2096998881 @default.
• W4313442754 cites W2097948046 @default.
• W4313442754 cites W2101345979 @default.
• W4313442754 cites W2118078989 @default.
• W4313442754 cites W2119914737 @default.
• W4313442754 cites W2136339108 @default.
• W4313442754 cites W2142795752 @default.
• W4313442754 cites W2150881991 @default.
• W4313442754 cites W2156302506 @default.
• W4313442754 cites W2159675211 @default.
• W4313442754 cites W2172089182 @default.
• W4313442754 cites W2294867706 @default.
• W4313442754 cites W2492547438 @default.
• W4313442754 cites W2581973599 @default.
• W4313442754 cites W2587057815 @default.
• W4313442754 cites W2655262992 @default.
• W4313442754 cites W2729334679 @default.
• W4313442754 cites W2886624030 @default.
• W4313442754 cites W2895220236 @default.
• W4313442754 cites W2897709693 @default.
• W4313442754 cites W2903623792 @default.
• W4313442754 cites W2912196744 @default.
• W4313442754 cites W2920781422 @default.
• W4313442754 cites W2954483101 @default.
• W4313442754 cites W2969623529 @default.
• W4313442754 cites W3001661683 @default.
• W4313442754 cites W3044786201 @default.
• W4313442754 cites W3093004857 @default.
• W4313442754 cites W3110073091 @default.
• W4313442754 cites W3126741775 @default.
• W4313442754 cites W3133305786 @default.
• W4313442754 cites W3149557634 @default.
• W4313442754 cites W3162293114 @default.
• W4313442754 cites W3182432706 @default.
• W4313442754 cites W3188319061 @default.
• W4313442754 cites W4205327277 @default.
• W4313442754 cites W4206841660 @default.
• W4313442754 cites W4221135319 @default.
• W4313442754 cites W4225413956 @default.
• W4313442754 cites W4250615339 @default.
• W4313442754 cites W4283735824 @default.
• W4313442754 cites W4285390129 @default.
• W4313442754 doi "https://doi.org/10.1016/j.ijrobp.2022.12.039" @default.
• W4313442754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36599398" @default.
• W4313442754 hasPublicationYear "2023" @default.
• W4313442754 type Work @default.
• W4313442754 citedByCount "0" @default.
• W4313442754 crossrefType "journal-article" @default.
• W4313442754 hasAuthorship W4313442754A5009011339 @default.
• W4313442754 hasAuthorship W4313442754A5017114190 @default.
• W4313442754 hasAuthorship W4313442754A5025056006 @default.
• W4313442754 hasAuthorship W4313442754A5034675773 @default.
• W4313442754 hasAuthorship W4313442754A5049269121 @default.
• W4313442754 hasAuthorship W4313442754A5065803127 @default.
• W4313442754 hasAuthorship W4313442754A5074475264 @default.
• W4313442754 hasAuthorship W4313442754A5076960814 @default.
• W4313442754 hasAuthorship W4313442754A5077200492 @default.
• W4313442754 hasConcept C121608353 @default.
• W4313442754 hasConcept C126322002 @default.
• W4313442754 hasConcept C126838900 @default.
• W4313442754 hasConcept C143998085 @default.
• W4313442754 hasConcept C156957248 @default.
• W4313442754 hasConcept C207103383 @default.
• W4313442754 hasConcept C2776015282 @default.
• W4313442754 hasConcept C2777154038 @default.

• next